Pangaea Data, Sanofi team up to boost rare disease detection with AI

Pangaea Data has entered a collaboration with Sanofi to deploy its AI platform for earlier detection of Alpha-1 Antitrypsin Deficiency in U.S. health systems and community care settings. The effort targets a condition that is widely underdiagnosed and could help clinicians find at-risk patients sooner using data already in electronic health records.

Why it matters: - Alpha-1 Antitrypsin Deficiency, or AATD, is a rare genetic disease that is often missed until after years of symptoms. - Up to 90% of people with AATD in the United States may remain undiagnosed. - Patients can wait five to eight years between symptom onset and diagnosis. - Earlier detection could help patients get screening, treatment and clinical trial access sooner. - The collaboration also points to a broader use case for AI-driven clinical decision support in respiratory and rare diseases.

What happened: - Pangaea Data entered a collaboration agreement with Sanofi. - The collaboration will deploy Pangaea’s guideline-configured AI platform to improve AATD detection in the United States. - The rollout will target a group of large health systems and low-resource community care settings. - The announcement was made June 22, 2026.

The details: - The platform is designed to find patients who may meet criteria for AATD evaluation using information already present in electronic health records. - The system integrates with existing tools and workflows, including EHRs, ambient listening tools, scheduling systems and communication platforms. - The platform processes structured and unstructured data, including clinical notes, in real time. - Insights are delivered at the point of care and through population health dashboards. - Clinicians can use the outputs to consider screening, treatment or clinical trial referral. - Health system leaders can use the population view to align resources and operational priorities. - The platform is intended to standardize care pathways, reduce missed diagnoses and support more timely management. - Sanofi is supporting the deployment. - Pangaea’s technology is intended to work without adding extra operational burden for clinicians, providers or patients. - Pangaea is based in South San Francisco and London.

Between the lines: - The collaboration addresses a common rare-disease problem: relevant signals already exist in records, but they are easy to overlook in routine care. - The emphasis on workflow integration suggests the partnership is aimed at adoption inside existing systems, not a standalone screening product. - Sanofi framed the effort as a way to help health systems identify patients earlier while keeping real-world data securely within the health system. - Pangaea framed the work as a scalable approach to earlier detection across chronic and rare hard-to-diagnose conditions. - The companies positioned AATD as the starting point for a wider respiratory and rare disease strategy.

What’s next: - The initial focus is AATD, with plans for broader care-gap support across respiratory and rare diseases at scale. - The collaboration aims to support earlier screening, improved guideline concordance and more equitable access to treatment and trials. - Pangaea will continue deploying its platform across health systems using existing clinical workflows. - Sanofi and Pangaea signaled interest in expanding the approach beyond AATD if the model proves effective.

The bottom line: - Pangaea and Sanofi are betting that AI embedded in routine care can surface overlooked rare disease cases earlier, without forcing clinicians to change how they work.